FDA Approves Dose Escalation Label Update For Puma's NERLYNX In Metastatic Breast Cancer

By RTTNews Staff Writer ✉ | Published: 7/1/2021 9:09 AM ET

Puma Biotechnology Inc. (PBYI) said that the U.S. Food and Drug Administration has approved dose escalation label update for the company's NERLYNX or neratinib in HER2-positive early stage and metastatic breast cancer.

The dose escalation of NERLYNX therapy demonstrated improved management and prevention of Grade 3 diarrhea.

Puma believes that utilizing dose escalation has the potential to improve the overall tolerability of NERLYNX and increase the average length of therapy, with the end result benefiting more patients battling breast cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech stocks Facing FDA Decision in January 2023

Biotech Stocks Facing FDA Decision In December 2022

Biotech Stocks Facing FDA Decision In November 2022

Editors Pick

Chevron Q4 Profit Up 25%, But Misses Estimates

Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it.

ZLINE Expands Recall Of Gas Ranges

Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units...

FDA Advisors Propose To Replace Primary COVID Shots With New Bivalent Shots

The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.

Latest Updates on COVID-19

U.S. Covid Metrics Signal Ease In Pandemic

FDA Advisors Propose To Replace Primary COVID Shots With New Bivalent Shots

US Covid Deaths Rise By 78% In 2 Weeks

78% Increase In US Covid Deaths In A Fortnight

Pentagon Repeals Memo Mandating Covid Vaccination For Armed Forces

COVID-19: Drugs in Development

Follow RTT

Most Read
Most Emailed

FDA Approves Dose Escalation Label Update For Puma's NERLYNX In Metastatic Breast Cancer

Johnson & Johnson Q4 Profit Down 26%, But Adj. EPS Tops Estimates

SkinnyDipped Dark Chocolate Nut Products Recalled

Cidara: FDA Committee Recommends FDA Approve Rezafungin For Candidemia, Invasive Candidiasis

Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma

Altamira: NASAR Interim Analysis Shows Superior Efficacy Of Bentrio In Seasonal Allergic Rhinitis

Intuitive Surgical Inc. Q4 Profit Decreases, misses estimates

Syros Gets Fast Track Designation In U.S. For Tamibarotene For Myelodysplastic Syndrome Treatment

Kura Oncology Announces FDA Clearance For IND Application For KO-2806

Emerson Says Committed To Proceed With National Instruments' Acquisition

Lonza FY22 Profit Up, Lifts Dividend; Sees Higher FY23 Sales, Weak Margin; Plans CHF 2 Bln Buyback

Abbott Issues FY23 Earnings, Sales Growth View - Update

FDA Advisors Propose To Replace Primary COVID Shots With New Bivalent Shots

Ford To Reportedly Cut 3,200 Jobs In Europe

Eastern Bankshares Down 11% As Q4 Earnings Fell Shy Of Estimates

Brown & Brown Q4 Profit Rises

Ipsen: CHMP Recommends Not To Grant Marketing Authorization For Palovarotene As Treatment For FOP

Archer-Daniels-Midland Q4 Profit Increases, beats estimates

Capital One Financial Corp. Q4 Profit Decreases, misses estimates

CNX Resources Corporation Q4 Income Climbs

Community Bank System Q4 Profit Beats Estimates

General Electric Co Q4 Earnings Summary

Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease

Syros Gets Fast Track Designation In U.S. For Tamibarotene For Myelodysplastic Syndrome Treatment

Newell Brands To Cut Jobs